Ipsen (IPN.PA) Announces At American Society of Clinical Oncology GI That ELECT® Clinical Trial Of Somatuline® In The Control Of Symptoms In GEP-NET1 Patients With Carcinoid Syndrome Met Its Primary Endpoint
1/17/2014 8:23:17 AM
PARIS--(BUSINESS WIRE)--Regulatory News:
Ipsen (Paris:IPN) (Euronext: IPN; ADR: IPSEY) today announced that the results of the ELECT® phase III clinical study with Somatuline® Autogel® / Somatuline® Depot® (lanreotide) Injection (hereafter referred to as Somatuline®) will be presented on Friday 17 January 2014 at the Gastrointestinal Cancers Symposium, San Francisco, CA, USA.
Help employers find you! Check out all the jobs and post your resume.
comments powered by